announcement, page-2

ASX/MEDIA RELEASE
1 October 2003
MANAGEMENT AND BOARD RESTRUCTURE
RELOCATION TO SYDNEY
Following the acquisition of the NuraPlex Nutraceutical complementary medicine business in
the USA and with the imminent commencement of Phase II clinical trials of PentrixTM, the
board and management of AustCancer has restructured to better position the company for
growth.
Chief Executive Officer, Mr Paul Hopper, will join the board and assume the position of
Managing Director, effective October 1st. Mr Hopper, 46, has nearly 25 years experience in
local and international public company markets, with almost half that time as the Managing
Director of Alpha Healthcare Limited, a diversified ASX listed health services group which he
co-founded in 1988 and ran until 1999. Under his leadership, Alpha Healthcare grew to a
$100 million pa turnover business employing over 2,000 staff.
Executive Chairman, Dr Roger Aston, will continue in his role and be responsible for the
technical management of AustCancer’s clinical trial and drug development programmes. Dr
Aston has more than 20 years of commercial and scientific experience in the
biopharmaceutical industry. Formerly CEO of Peptech Limited and Biokine Technology
Limited, Dr Aston was also Chairman of Cambridge Drug Discovery and Director of
Cambridge Antibody Technology. Dr Aston is the founder and CEO of pSiMedica (UK), a UK
biomaterials company.
Both Dr Aston and Mr Hopper will be based in AustCancer’s Head Office which is to be
relocated to Sydney in late October.
Dr Alistair Cowden will resign as Managing Director effective October 1st and remain a
director and consultant.
An incentive package for Mr Hopper and Dr Aston has been negotiated and will be put to
shareholders at the company’s AGM in November. Mr Hopper has been awarded, subject to
meeting performance criteria and completing a period of service with the company, 2 million
options exercisable at 20 cents and expiring on December 31, 2006. Dr Aston has also been
awarded 2 million options on similar terms subject to cancellation of existing options held by
him.
- END -